{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:00:31Z","timestamp":1787162431203,"version":"build-2736575974"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":276,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.clinsp.2023.100291","type":"journal-article","created":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T20:19:42Z","timestamp":1698524382000},"page":"100291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer"],"prefix":"10.1016","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0044-9657","authenticated-orcid":false,"given":"Qi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3195-219X","authenticated-orcid":false,"given":"Lingli","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6071-4572","authenticated-orcid":false,"given":"Ying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1526-9710","authenticated-orcid":false,"given":"Hongwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7574-0066","authenticated-orcid":false,"given":"Zhengying","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2230-7767","authenticated-orcid":false,"given":"Fei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clinsp.2023.100291_bib0001","doi-asserted-by":"crossref","first-page":"900","DOI":"10.20892\/j.issn.2095-3941.2020.0523","article-title":"Breast cancer incidence and mortality in women in China: temporal trends and projections to 2030","volume":"18","author":"Lei","year":"2021","journal-title":"Cancer Biol Med"},{"issue":"4","key":"10.1016\/j.clinsp.2023.100291_bib0002","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming endocrine resistance in breast cancer","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.clinsp.2023.100291_bib0003","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinsp.2023.100291_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108602","article-title":"Ribociclib, a selective cyclin D kinase 4\/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo","volume":"112","author":"Xiong","year":"2019","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"10.1016\/j.clinsp.2023.100291_bib0005","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): A randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.clinsp.2023.100291_bib0006","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinsp.2023.100291_bib0007","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejca.2023.02.007","article-title":"Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive \/human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study)","volume":"184","author":"Wang","year":"2023","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.clinsp.2023.100291_bib0008","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/s41591-021-01562-9","article-title":"DAWNA-1 Study Consortium. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial","volume":"27","author":"Xu","year":"2021","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.clinsp.2023.100291_bib0009","doi-asserted-by":"crossref","first-page":"769","DOI":"10.20892\/j.issn.2095-3941.2022.0277","article-title":"Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification","volume":"19","author":"Li","year":"2022","journal-title":"Cancer Biol Med"},{"issue":"7","key":"10.1016\/j.clinsp.2023.100291_bib0010","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(17)30376-5","article-title":"Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Baselga","year":"2017","journal-title":"Lancet Oncol"},{"issue":"283","key":"10.1016\/j.clinsp.2023.100291_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aaa4442","article-title":"PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer","volume":"7","author":"Bosch","year":"2015","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.clinsp.2023.100291_bib0012","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.clbc.2017.10.014","article-title":"A Phase I trial of the PI3K inhibitor buparlisib combined with capecitabine in patients with metastatic breast cancer","volume":"18","author":"McRee","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"7","key":"10.1016\/j.clinsp.2023.100291_bib0013","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1158\/1078-0432.CCR-15-1745","article-title":"A phase I trial of BKM120 (buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive metastatic breast cancer","volume":"22","author":"Ma","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.clinsp.2023.100291_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.37120","article-title":"Association of performance status with survival in patients with advanced non-small cell lung cancer treated with pembrolizumab monotherapy","volume":"4","author":"Sehgal","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinsp.2023.100291_bib0015","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinsp.2023.100291_bib0016","unstructured":"U.S. Department of health and human services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Available from:https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5\/7.pdf. [15 November 2018]."},{"issue":"1","key":"10.1016\/j.clinsp.2023.100291_bib0017","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-021-00271-2","article-title":"A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4\/6 inhibitor in Chinese patients with advanced breast cancer","volume":"9","author":"Zhang","year":"2021","journal-title":"Biomark Res"},{"issue":"4","key":"10.1016\/j.clinsp.2023.100291_bib0018","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JGO.2016.008318","volume":"3","author":"Iwata","year":"2017","journal-title":"J Glob Oncol"},{"issue":"11","key":"10.1016\/j.clinsp.2023.100291_bib0019","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/2042098617722516","article-title":"Gastrointestinal adverse effects of cyclin-dependent kinase 4 and 6 inhibitors in breast cancer patients: a systematic review and meta-analysis","volume":"8","author":"Shohdy","year":"2017","journal-title":"Ther Adv Drug Saf"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593223001278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593223001278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T21:37:30Z","timestamp":1725053850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593223001278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":19,"alternative-id":["S1807593223001278"],"URL":"https:\/\/doi.org\/10.1016\/j.clinsp.2023.100291","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinsp.2023.100291","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 HCFMUSP. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"100291"}}